Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer (HER2+ mCRC): A Systematic Literature Review and Meta-Analysis of Clinical Outcomes

Video
Related Videos
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
A panel of 4 experts on colorectal cancer
Heinz-Josef Lenz, MD, FACP
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Scott Kopetz, MD, PhD, FACP
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Related Content
Benjamin A. Weinberg, MD

Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy

May 10th 2024
Article
John H. Strickler, MD

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023
Podcast
Dana Walker, MD, MSCE

EMA Validates MAA for Frontline Nivolumab/Ipilimumab for MSI-H/dMMR mCRC

May 6th 2024
Article
Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022
Podcast
Guido Baechler

Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection

April 25th 2024
Article
Heinz-Josef Lenz, MD, University of Southern California Norris Comprehensive Cancer Center

Retrospective Data Show Association Between HER2 Expression and Survival Outcomes in mCRC

April 25th 2024
Article